Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Nintedanib 200 mg Capsule vs 2x100 mg Capsules
NCT02572752Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nintedanib in non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point at 72 hours and Maximum measured concentration of the analyte in plasma at 72 hours. Started Aug 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02572752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572752.